Comparison · NCT04985942-sae
Lumateperone 42 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lumateperone 42 mg vs Placebo: serious adverse events. Trial comparisons, record NCT04985942-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04985942-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00415 | 0.000733 | 0.0231 | wilson | |
| Risk in group 2 | 0.00412 | 0.000727 | 0.0229 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0000342 | -0.0191 | 0.0193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.0634 | 16 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.0627 | 16.2 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Lumateperone 42 mg than on Placebo | 29,300 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lumateperone 42 mg | Lumateperone: Lumateperone 42 mg capsules administered orally, once daily. | 1 | 241 | EG000 |
| Group 2 | Placebo | Placebo: Matching capsules administered orally, once daily. | 1 | 243 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From signing ICF until end of study procedures (~9 weeks), including 6 weeks of double-blind treatment.
Source ClinicalTrials.gov
Trial
- Title
- Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT number
- NCT04985942
- Phases
- PHASE3
- Conditions
- Major Depressive Disorder
- Interventions
- Lumateperone, Placebo
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Results first posted
- 2025-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04985942?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04985942-sae